Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety
Open Access
- 25 February 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (3) , 34
Abstract
Targeted protein degradation using small chimeric molecules, such as proteolysis-targeting chimeras (PROTACs) and specific and nongenetic inhibitors of apoptosis protein [IAP]-dependent protein erasers (SNIPERs), is a promising technology in drug discovery. We recently developed a novel class of chimeric compounds that recruit the aryl hydrocarbon receptor (AhR) E3 ligase complex and induce the AhR-dependent degradation of target proteins. However, these chimeras contain a hydrophobic AhR E3 ligand, and thus, degrade target proteins even in cells that do not express AhR. In this study, we synthesized new compounds in which the AhR ligands were replaced with a hydrophobic adamantane moiety to investigate the mechanisms of AhR-independent degradation. Our results showed that the compounds, 2, 3, and 16 induced significant degradation of some target proteins in cells that do not express AhR, similar to the chimeras containing AhR ligands. However, in cells expressing AhR, 2, 3, and 16 did not induce the degradation of other target proteins, in contrast with their response to chimeras containing AhR ligands. Overall, it was suggested that target proteins susceptible to the hydrophobic tagging system are degraded by chimeras containing hydrophobic AhR ligands even without AhR.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP19K07009)
This publication has 29 references indexed in Scilit:
- PROteolysis TArgeting Chimeras (PROTACs) — Past, present and futureDrug Discovery Today: Technologies, 2019
- Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinaseScientific Reports, 2018
- Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistanceCommunications Biology, 2018
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein LigandsJournal of Medicinal Chemistry, 2017
- In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)Journal of Biological Chemistry, 2017
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2016
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer TherapyCurrent Cancer Drug Targets, 2016
- Phthalimide conjugation as a strategy for in vivo target protein degradationScience, 2015
- Catalytic in vivo protein knockdown by small-molecule PROTACsNature Chemical Biology, 2015
- Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategyBioorganic & Medicinal Chemistry Letters, 2012